Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 6/20 | 0.38 |
| ▸ | CA12 | O43570 | 4/20 | 0.38 |
| ▸ | CA1 | P00915 | 4/20 | 0.38 |
| ▸ | CA4 | P22748 | 4/20 | 0.38 |
| ▸ | CA9 | Q16790 | 4/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.35 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.35 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.35 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14005135 | 0.92 | MEN1 (0.41) | MEN1KMT2ASMN1; SMN2CA2CA12 | |
| SCHEMBL26255469 | 0.92 | MEN1 (0.44) | MEN1KMT2ASMN1; SMN2CA2CA12 | |
| SCHEMBL15757921 | 0.92 | SMN1; SMN2 (0.42) | MEN1KMT2ASMN1; SMN2CA2CA12 | |
| SCHEMBL27138688 | 0.92 | SMN1; SMN2 (0.42) | MEN1KMT2ASMN1; SMN2CA2CA12 | |
| SCHEMBL16853233 | 0.91 | MEN1 (0.39) | MEN1KMT2ASMN1; SMN2CA2CA12 | |
| SCHEMBL24796096 | 0.90 | MEN1 (0.40) | MEN1KMT2ASMN1; SMN2CA2CA12 | |
| SCHEMBL20197917 | 0.90 | KDM4E (0.46) | MEN1KMT2ASMN1; SMN2CA2L3MBTL1 | |
| SCHEMBL21748011 | 0.90 | KDM4E (0.46) | MEN1KMT2ASMN1; SMN2CA2L3MBTL1 | |
| SCHEMBL18120313 | 0.90 | MEN1 (0.44) | MEN1KMT2ASMN1; SMN2L3MBTL1KDM4E | |
| SCHEMBL24894030 | 0.90 | MEN1 (0.44) | MEN1KMT2ASMN1; SMN2CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473328-B2 | Method for modification of peptides immobilized on a solid support by traceless reductively cleavable linker molecules | Belyntic GmbH (DE) | 2025-11-18 | — | — | US | claimed |
| US-12473328-B2 | Method for modification of peptides immobilized on a solid support by traceless reductively cleavable linker molecules | Belyntic GmbH (DE) | 2025-11-18 | — | — | US | disclosed |
| EP-4010352-B1 | A METHOD FOR MODIFICATION OF PEPTIDES IMMOBILIZED ON A SOLID SUPPORT BY TRACELESS REDUCTIVELY CLEAVABLE LINKER MOLECULES | GYROS PROTEIN TECH AB (SE) | 2023-10-18 | — | — | EP | disclosed |
| US-11730726-B2 | Dimeric immuno-modulatory compounds against cereblon-based mechanisms | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20220363713-A1 | A METHOD FOR MODIFICATION OF PEPTIDES IMMOBILIZED ON A SOLID SUPPORT BY TRACELESS REDUCTIVELY CLEAVABLE LINKER MOLECULES | Belyntic GmbH (DE) | 2022-11-17 | — | — | US | disclosed |
| EP-0815091-B1 | POLYAZACYCLOALKANE COMPOUNDS | NYCOMED IMAGING AS (NO) | 2002-06-12 | — | — | EP | disclosed |
| US-5705637-A | Polyazacycloalkane compounds | NYCOMED IMAGING AS (NO) | 1998-01-06 | — | — | US | disclosed |
| US-5677446-A | Polyazacycloalkane compounds | NYCOMED IMAGING AS (NO) | 1997-10-14 | — | — | US | disclosed |
| US-5631368-A | Polyazacycloalkane compounds | NYCOMED IMAGING AS (NO) | 1997-05-20 | — | — | US | disclosed |
| WO-1996028433-A1 | POLYAZACYCLOALKANE COMPOUNDS | NYCOMED IMAGING A.S (NO) | 1996-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11730726-B2 | Dimeric immuno-modulatory compounds against cereblon-based mechanisms | CRBN, CD4, CD74 | MEN1 2966/4885KMT2A 3583/4885SMN1; SMN2 1672/4885 |
| US-20220363713-A1 | A METHOD FOR MODIFICATION OF PEPTIDES IMMOBILIZED ON A SOLID SUPPORT BY TRACELESS REDUCTIVELY CLEAVABLE LINKER MOLECULES | PTMS, VIP, HM13 | MEN1 2426/4885KMT2A 2598/4885SMN1; SMN2 3665/4885 |
| US-12473328-B2 | Method for modification of peptides immobilized on a solid support by traceless reductively cleavable linker molecules | PTMS, VIP, HM13 | MEN1 2614/4885KMT2A 2599/4885SMN1; SMN2 3924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.